Aktis Oncology, Inc.
NASDAQ:AKTSBiotechnology
Healthcare
$16.10 +0.47%
+$0.11 today
- Market cap
- $865.32M
- Beta
- 1.10
- P/E (TTM)
- -28.7
- EPS (TTM)
- -$0.82
52W Low $14.72High $29.16
Volume 0.44M
Average 0.33M
Balance Sheet
Inspect the capital base behind the business.
Assets
$264.88M
FY 2025 · Annual
-18.8% YoYLiabilities
$411.03M
FY 2025 · Annual
-0.7% YoYEquity
-$146.15M
FY 2025 · Annual
Balance Sheet
USD
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $371.6M |
| Short-term Investments | $166.9M |
| Receivables | $2.2M |
| Other Current | $3.3M |
| Total Current Assets | $543.9M |
| PP&E (Net) | $28.1M |
| Long-term Investments | $1.1M |
| Other Non-current | $3.6M |
| Total Non-current Assets | $32.9M |
| Total Assets | $576.8M |
Analysis
Selected assets total $576.8M for Latest. The largest visible component is Cash & Equivalents at $371.6M, about 64.4% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 12, 2026 | |
| 10-Q | Quarterly report | Nov 12, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 24, 2026 | |
| 10-Q | Quarterly report | Aug 13, 2026 | |
| 8-K | Current report | Aug 13, 2026 |
How much cash does AKTS have?
Aktis Oncology, Inc. (AKTS) reported $37.78M in cash and equivalents in fiscal 2025.
How much debt does AKTS carry?
Aktis Oncology, Inc. (AKTS) reported $11.55M of total debt, with net debt of -$26.24M.
Continue the stock analysis
Jump to another research area for this company.